J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
Portfolio Pulse from
The FDA has approved Johnson & Johnson's supplemental New Drug Application (sNDA) for Spravato, allowing its use as a monotherapy for adults with treatment-resistant depression.
January 22, 2025 | 5:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson received FDA approval for Spravato as a monotherapy for treatment-resistant depression, potentially boosting its market share in the depression treatment sector.
The FDA approval allows J&J to market Spravato as a standalone treatment, potentially increasing its sales and market presence in the depression treatment market. This regulatory milestone is likely to positively impact JNJ's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100